Search
Robenidine
go.drugbank.com/drugs/DB11542ExperimentalVet approvedDespite the availability of other agents to treat coccidiosis, robenidine has been proven to be effective in delaying the development of antibiotic resistance through intermittent and rotating use with … Robenidine is used to control coccidiosis, a lethal infection in poultry which has shown a significant economic burden.
Epofolate
go.drugbank.com/drugs/DB12266Investigationaland neutropenia appear to have been less frequent and less severe as compared to epothilones. … Epofolate (BMS-753493) is a folate conjugate of the epothilone analog BMS-748285 that was designed to selectively target folate receptor expressing cancer cells.
Ginisortamab
go.drugbank.com/drugs/DB18863InvestigationalGinisortamab is under investigation in clinical trial NCT04393298 (A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced
Depulfavirine
go.drugbank.com/drugs/DB18890InvestigationalDepulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).
Phytochlorin
go.drugbank.com/drugs/DB19265InvestigationalPhytochlorin is under investigation in clinical trial NCT06311890 (Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(pdt) With Chlorin-e6 in Treating Moderate to Severe Acne
Etofibrate
go.drugbank.com/drugs/DB08983ExperimentalEtofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. … These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Lexacalcitol
go.drugbank.com/drugs/DB03451ExperimentalIt is known to target the vitamin D3 receptor. … This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Itepekimab
go.drugbank.com/drugs/DB16206InvestigationalItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe
Itolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
AT-7519
go.drugbank.com/drugs/DB08142InvestigationalAT7519 is a selective inhibitor of certain Cyclin Dependent Kinases (CDKs) leading to tumour regression. It is developed by Astex for the treatment of solid tumours and haematological malignancies.